Finding Your CAR: The Road Ahead for Engineered T Cells.

Area of Science:

• Immunotherapy
• Cellular Therapy
• Cancer Research

Background:

• Chimeric antigen receptor (CAR) T-cell therapy engineers T cells to target tumor antigens, revolutionizing cancer treatment.
• Pathology laboratories are integral to the multi-step CAR T-cell therapy process, from diagnosis to post-treatment monitoring.

Purpose of the Study:

• To review existing and emerging technologies for pathology laboratories in CAR T-cell therapy.
• To highlight the expanding role of pathology in supporting advanced cellular therapies and translational research.

Main Methods:

• Review of current technologies for antigen detection (flow cytometry, immunohistochemistry).
• Discussion of methods for monitoring CAR T-cell persistence, phenotype, and tumor microenvironment.
• Exploration of emerging technologies for CAR T-cell control and side effect evaluation.

Main Results:

• Pathology labs are essential for identifying targetable antigens and detecting resistance mechanisms like antigen loss.
• Monitoring CAR T-cell function, tumor infiltration, and the tumor microenvironment are key pathological roles.
• Pathology supports the evaluation of CAR T-cell therapy efficacy and adverse events, including cytokine release syndrome.

Conclusions:

• Pathology laboratories are indispensable partners in CAR T-cell therapy, providing critical diagnostic and monitoring capabilities.
• The field presents significant translational research opportunities for pathology in adoptive cellular therapy.
• Advanced diagnostic and monitoring tools are needed to optimize CAR T-cell therapy outcomes and safety.